IANNONE, LUIGI FRANCESCO
 Distribuzione geografica
Continente #
AS - Asia 3.196
NA - Nord America 2.849
EU - Europa 1.904
SA - Sud America 377
AF - Africa 74
OC - Oceania 51
Totale 8.451
Nazione #
US - Stati Uniti d'America 2.773
CN - Cina 1.121
RU - Federazione Russa 976
SG - Singapore 889
IT - Italia 429
HK - Hong Kong 346
KR - Corea 342
BR - Brasile 292
VN - Vietnam 198
FR - Francia 109
IN - India 92
IE - Irlanda 69
FI - Finlandia 65
DE - Germania 60
MX - Messico 53
GB - Regno Unito 52
AU - Australia 51
ID - Indonesia 49
SE - Svezia 40
AR - Argentina 34
NL - Olanda 26
JP - Giappone 24
CH - Svizzera 22
NG - Nigeria 18
BD - Bangladesh 16
EC - Ecuador 16
BJ - Benin 14
CA - Canada 14
IQ - Iraq 14
JO - Giordania 14
ZA - Sudafrica 14
PK - Pakistan 13
CO - Colombia 10
IR - Iran 10
CL - Cile 9
MA - Marocco 9
UA - Ucraina 9
PH - Filippine 8
EG - Egitto 7
MY - Malesia 7
PL - Polonia 7
TR - Turchia 7
TW - Taiwan 7
ES - Italia 6
PT - Portogallo 6
SA - Arabia Saudita 6
UZ - Uzbekistan 6
AT - Austria 5
LT - Lituania 5
PE - Perù 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
BE - Belgio 4
CI - Costa d'Avorio 4
TH - Thailandia 4
TN - Tunisia 4
KE - Kenya 3
KG - Kirghizistan 3
LB - Libano 3
NP - Nepal 3
VE - Venezuela 3
AL - Albania 2
AZ - Azerbaigian 2
BG - Bulgaria 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
GR - Grecia 2
KZ - Kazakistan 2
MK - Macedonia 2
UY - Uruguay 2
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
GH - Ghana 1
GI - Gibilterra 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
PA - Panama 1
TT - Trinidad e Tobago 1
Totale 8.451
Città #
Santa Clara 1.024
Singapore 688
Hefei 473
Ashburn 456
Seoul 340
Hong Kong 306
San Jose 176
Beijing 111
Council Bluffs 79
Los Angeles 72
Ho Chi Minh City 69
Moscow 68
Dublin 64
Florence 64
Lauterbourg 56
Kent 55
The Dalles 55
Buffalo 47
Melbourne 43
Helsinki 42
Milan 41
Chicago 40
Hanoi 39
Bengaluru 37
Rome 35
Jakarta 34
Dallas 30
São Paulo 26
Munich 25
New York 25
Mumbai 23
Paris 23
Shanghai 22
Altamura 20
Lawrence 20
Abuja 18
West Jordan 18
Lappeenranta 17
London 17
Chandler 16
Coppell 15
Tokyo 15
Cotonou 14
Fontebuona 14
Gustavo Adolfo Madero 13
Haiphong 13
Washington 12
Salt Lake City 11
Wilmington 11
Bern 10
Bologna 10
Houston 10
Princeton 10
Rio de Janeiro 10
Seattle 10
Boston 9
Brescia 9
Frankfurt am Main 9
Johannesburg 9
Lausanne 8
Orem 8
Phoenix 8
Turin 8
Atlanta 7
Benito Juarez 7
Gioia Tauro 7
Guayaquil 7
Nagoya 7
Porto Alegre 7
Sydney 7
Buenos Aires 6
Elk Grove Village 6
Fairfield 6
Guangzhou 6
Quito 6
Turku 6
Warsaw 6
Yubileyny 6
Baghdad 5
Boardman 5
Brooklyn 5
Changsha 5
Chennai 5
Curitiba 5
Denver 5
Kyiv 5
Lisbon 5
Medford 5
Mexico City 5
Naples 5
Philadelphia 5
San Mateo 5
Shenzhen 5
Taichung 5
Tashkent 5
Tianjin 5
Toronto 5
Trento 5
Venustiano Carranza 5
Woodbridge 5
Totale 5.267
Nome #
Gut microbiota manipulation as an epilepsy treatment 371
Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and Tolerability 272
Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score 262
Current status and future perspectives in HER2 positive advanced gastric cancer 197
Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study 186
Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ) 172
Perineural invasion score system and clinical outcomes in resected pancreatic cancer patients 164
Microbiota-gut brain axis involvement in neuropsychiatric disorders 163
Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment 162
The microbiota-gut-brain axis and epilepsy from a multidisciplinary perspective: Clinical evidence and technological solutions for improvement of in vitro preclinical models 160
Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine 160
Endometriosis and the diagnosis of different forms of migraine: an association with dysmenorrhoea 160
The trpa1 channel amplifies the oxidative stress signal in melanoma 160
Tumor-Infiltrating Lymphocyte Recognition in Primary Melanoma by Deep Learning Convolutional Neural Network 159
Non-neuronal TRPA1 encodes mechanical allodynia associated with neurogenic inflammation and partial nerve injury in rats 157
Appropriate use of generic and branded antiseizure medications in epilepsy: Updated recommendations from the Italian League Against Epilepsy (LICE) 154
A real‐world comparison among third‐generation antiseizure medications: Results from the COMPARE study 152
Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine 148
Spatial Proximity and Relative Distribution of Tumor-Infiltrating Lymphocytes and Macrophages Predict Survival in Melanoma 146
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study 145
The Microbiome-Gut-Brain axis regulates social cognition & craving in young binge drinkers 143
Emerging Pharmacological Treatments for Migraine in the Pediatric Population 139
Schwann cell C5aR1 co-opts inflammasome NLRP1 to sustain pain in a mouse model of endometriosis 138
Clinically relevant drug interactions between statins and antidepressants 136
Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: a prospective case series 134
Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy 132
Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study) 130
Can we 'seize' the gut microbiota to treat epilepsy? 129
Antiseizure medications for the prophylaxis of migraine during the anti-CGRP drugs era 129
Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs 127
The role of TRP ion channels in migraine and headache 127
First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat 126
Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study 125
Status epilepticus in pregnancy: a literature review and a protocol proposal 125
An evolving machine-learning-based algorithm to early predict response to anti-CGRP monoclonal antibodies in patients with migraine 122
Utilization patterns, cardiovascular risk, and concomitant serotoninergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany 122
Pharmacology of new and developing intravenous therapies for the management of seizures and epilepsy 120
Assessing knowledge and attitudes toward epilepsy among schoolteachers and students: Implications for inclusion and safety in the educational system 120
Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study 120
Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome 120
Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand? 120
A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report 118
COVID-19 pneumonia during long-term migraine prophylaxis with fremanezumab: a case report 118
Renal denervation for resistant hypertension 116
The gut microbiome and efficacy of cancer immunotherapy 116
Migraine Treatment: Towards New Pharmacological Targets 115
Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY) 114
Ixekizumab May Improve Renal Function in Psoriasis 112
Association of anti‐calcitonin gene‐related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study 110
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice 110
Patterns of anti‐CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy 107
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study 106
Neuronal and non-neuronal TRPA1 as therapeutic targets for pain and headache relief 104
Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine 102
Gut microbiota and psychogenic non-epileptic seizures: i can feel it in the belly 101
Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: A case series and literature review 95
Management of status epilepticus in patients with liver or kidney disease: a narrative review 94
Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study 92
Exploring the multifaceted characteristics of aura in migraine: A multicenter, cross-sectional study 77
Impact of duration of chronic migraine on long‐term effectiveness of monoclonal antibodies targeting the calcitonin gene‐related peptide pathway—A real‐world study 76
The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a "real world" context: focus on temporal lobe epilepsy 72
The potential role of interventions impacting on gut-microbiota in epilepsy 67
Immunotherapy-related biomarkers: Confirmations and uncertainties 66
Morpho-phenotypic characterization of melanoma brain metastases immune microenvironment: A multicentre retrospective study 15
Totale 8.537
Categoria #
all - tutte 25.553
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.553


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202274 0 0 0 0 0 0 0 18 15 10 15 16
2022/2023314 13 51 15 9 1 37 35 12 16 29 68 28
2023/2024587 13 31 57 34 39 61 33 136 59 61 50 13
2024/20253.288 92 309 184 418 804 463 124 152 109 191 161 281
2025/20264.274 504 711 795 581 377 144 444 221 204 233 60 0
Totale 8.537